Previsão

Não temos dados de analistas para esta empresa.

Notícias Ir para o feed de notícias

Cantargia emphasizes IL1RAP focus and presents nadunolimab data at H.C. Wainwright conference

At the conference Cantargia reaffirmed its strategy to pursue IL1RAP as a target for cancer and inflammatory treatments, calling the scientific rationale promising while noting typical clinical development risks. Nadunolimab (CAN04) showed a median overall survival of 13.2 months in PDAC in the CANFOUR study, and in an MDS/AML phase‑I‑B cohort 5 of 5 evaluable patients achieved complete remissions. A potential partnership with Otsuka worth up to $613 million and a broad IL1RAP antibody platform support the strategy; other key milestones include interim data at ASH, a full data set in 2025, and the planned start of the nadunolimab/daraxonrasib combination study. » Mais em de.investing.com
Cantargia to publish quarterly figures for 31 December 2025 on 20 February 2026

Cantargia will publish figures for the quarter ending 31 December 2025 on 20 February 2026. One analyst expects earnings per share of -0.190 SEK (previous year -0.210 SEK) and revenue of 0.0 million SEK, as in the year-ago quarter. For the past fiscal year one analyst forecasts earnings of 0.440 SEK per share, while three analysts on average estimate annual revenue at 218.4 million SEK (previous year 0.0 million SEK). » Mais em finanzen.net
Cantargia records first profit after transformative Otsuka agreement

Cantargia reports for Q3 2025 its first revenue (SEK 308.7m) and net profit (SEK 265.5m), driven by the license agreement with Otsuka for the CAN10 program. The deal delivered a USD 33m upfront payment, up to USD 580m in milestones and double‑digit royalties, and strengthened liquidity to SEK 339m. Operating cash flow and the balance sheet improved markedly, while R&D expenses fell and administrative costs rose due to deal‑related expenses. Cantargia plans a registration‑relevant study for nadunolimab in mid‑2026; however, the company still expects negative EPS for Q4 2025 and 2026, so shareholders remain cautious. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, Cantargia AB registou receitas de € 8,57 mil e um ganho líquido de -€ 2,96 mi

(EUR)	junho de 2026	YoY
Receitas	8,57 mil	-
Ganho bruto	-17,15 mil	78,27%
Ganho líquido	-2,96 mi	15,98%
EBITDA	-3,19 mi	4,80%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 39,65 mi
Número de ações	281,95 mi
Máximo/mínimo de 52 semanas	€ 0,58 - € 0,14
Dividendos	Não
Beta	1,59
PER (PE Ratio)	2,33
PEG (PEG Ratio)	0,01
P/VC (PB Ratio)	1,49
P/V (PS Ratio)	1,41

Perfil da empresa

Cantargia AB (publ), ein Biotechnologieunternehmen, beschäftigt sich mit der Erforschung und Entwicklung von Antikörper-basierten Behandlungen für lebensbedrohliche Krankheiten. Das Unternehmen entwickelt CAN04, einen Antikörper gegen das Interleukin-1-Rezeptor-Accessory-Protein (IL1RAP) zur Erkennung von Krebszellen und zur Stimulierung des natürlichen Immunsystems, um diese Zellen zu zerstören, sowie zur Blockierung der Tumorentzündung, die durch das Interleukin-1-System ausgelöst wird, und befindet sich in einer klinischen Studie der Phase IIa; CAN10, ein Antikörper gegen IL1RAP zur Behandlung von Autoimmun- und Entzündungskrankheiten, einschließlich systemischer Sklerose und Myokarditis, befindet sich in einer präklinischen Studie. Außerdem entwickelt das Unternehmen CANxx-Antikörper gegen IL1RAP. Das Unternehmen hat Kooperationsvereinbarungen mit Patheon Biologics BV und BioWa Inc. für die Herstellung und Produktion von CAN04 sowie mit Specialized Medical Services-oncology BV für die klinische Studie von CAN04. Cantargia AB (publ) wurde im Jahr 2010 gegründet und hat seinen Sitz in Lund, Schweden.